Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.48 |
| ▸ | HTR3B | O95264 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11844645 | 1.00 | NPC1 (0.48) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL5301634 | 1.00 | NPC1 (0.48) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL11693056 | 0.82 | NPC1 (0.61) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL11693067 | 0.82 | NPC1 (0.61) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL17446281 | 0.82 | NPC1 (0.61) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL1405393 | 0.82 | NPC1 (0.61) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL255052 | 0.82 | NPC1 (0.61) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL7047723 | 0.77 | — | — | |
| SCHEMBL3339447 | 0.76 | MAPT (0.74) | NPC1MAPTRAB9AL3MBTL1MAPK1 | |
| SCHEMBL3339449 | 0.76 | MAPT (0.74) | NPC1MAPTRAB9AL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250180508-A1 | QUANTITATIVE LIPIDOMIC ANALYSIS, METHODS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-06-05 | — | — | US | disclosed |
| EP-2531463-B1 | HYPERVALENT RADIOACTIVE ASTATINE OR IODINE COMPOUNDS, AND PREPARATION METHODS THEREOF | INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM) (FR) | 2017-11-01 | — | — | EP | disclosed |
| EP-1934238-B1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170080097-A1 | DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| WO-2015162630-A1 | NOVEL PROCESSES FOR PREPARING TRIAZOLO [4,5-D]- PYRIMIDINES, INCLUDING TICAGRELOR, VIANEW INTERMEDIATES AND NEW ROUTE OF SYNTHESIS. | ANLON CHEMICAL RESEARCH ORGANIZATION (IN) | 2015-10-29 | — | — | WO | disclosed |
| US-5760042-A | INHIBITOR OF PHOSPHODIESTERASES | SANKYO COMPANY, LIMITED (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5616600-A | Griseolic acid compounds and their use as a phosphodiesterase inhibitor | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| US-5556975-A | CYCLIC GMP PHOSPHODIESTERASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5532369-A | NUCLEOTIDE INHIBITORS OF PHOSPHODIESTERASE | SANKYO COMPANY, LIMITED (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5498819-A | INHIBITORS OF PHOSPHODIESTERASE AS NEUROTROPIC AGENTS, ANTIINFLAMMATORY AGENTS, MUSCLE RELAXANTS, ANTICARCINOGENIC AGENTS AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0318060-B1 | Griseolic acid derivatives, their preparation and their use | SANKYO CO (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0319050-B1 | Griseolic acid derivatives, their preparation and their use | SANKYO CO (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0200522-B1 | PROCESS FOR PREPARING GRISEOLIC ACID DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0319050-A2 | Griseolic acid derivatives, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1989-06-07 | — | — | EP | disclosed |
| EP-0318060-A2 | Griseolic acid derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4783532-A | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0200522-A2 | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080097-A1 | DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS | CCL2, CD63, CD69 | NPC1 3330/4885MAPT 2815/4885RAB9A 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.